1-14 of 14
Robert L. Coleman
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Rational Combination of CRM1 Inhibitor Selinexor and Olaparib Shows Synergy in Ovarian Cancer Cell Lines and Mouse Models

Katelyn F. Handley, Cristian Rodriguez-Aguayo, Shaolin Ma, Elaine Stur, Robiya Joseph, Emine Bayraktar, Santosh K. Dasari, Nghi Nguyen, Reid T. Powell, Mary Sobieski, Cristina Ivan, Mark Kim, Sujanitha Umamaheswaran, Deanna Glassman, Yunfei Wen, Paola Amero, Clifford Stephan, Robert L. Coleman, Yosef Landesman, Shannon N. Westin, Prahlad T. Ram, Anil K. Sood
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2021) 20 (12): 2352–2361.
https://doi.org/10.1158/1535-7163.MCT-21-0370
Published: 03 December 2021
View article titled, Rational Combination of CRM1 Inhibitor Selinexor and Olaparib Shows Synergy in Ovarian Cancer Cell Lines and Mouse Models
Open the PDF for Rational Combination of CRM1 Inhibitor Selinexor and Olaparib Shows Synergy in Ovarian Cancer Cell Lines and Mouse Models in another window
Includes: Supplementary data
Journal Articles

Abstract P046: ENGOT-ov60/GOG3052/RAMP 201: A phase 2 study of VS-6766 (dual RAF/MEK inhibitor) alone and in combination with defactinib (FAK inhibitor) in recurrent low-grade serous ovarian cancer (LGSOC)

Susana N. Banerjee, Bradley J. Monk, Els Van Nieuwenhuysen, Kathleen N. Moore, Ana Oaknin, Michel Fabbro, Nicoletta Columbo, David M. O’Malley, Robert L. Coleman, Jonathan Pachter, Andrew Koustenis, Gloria Patrick, Lorna Leonard, Rachel Grisham
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2021) 20 (12_Supplement): P046.
https://doi.org/10.1158/1535-7163.TARG-21-P046
Published: 01 December 2021
View article titled, Abstract P046: ENGOT-ov60/GOG3052/RAMP 201: A phase 2 study of VS-6766 (dual RAF/MEK inhibitor) alone and in combination with defactinib (FAK inhibitor) in recurrent low-grade serous ovarian cancer (LGSOC)
Journal Articles

Enhanced Immunotherapy with LHRH-R Targeted Lytic Peptide in Ovarian Cancer

Mark Seungwook Kim, Shaolin Ma, Anca Chelariu-Raicu, Carola Leuschner, Hector W. Alila, Sanghoon Lee, Robert L. Coleman, Anil K. Sood
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2020) 19 (11): 2396–2406.
https://doi.org/10.1158/1535-7163.MCT-20-0030
Published: 03 November 2020
View article titled, Enhanced Immunotherapy with LHRH-R Targeted Lytic Peptide in Ovarian Cancer
Open the PDF for Enhanced Immunotherapy with LHRH-R Targeted Lytic Peptide in Ovarian Cancer in another window
Includes: Supplementary data
Journal Articles

NRG1/ERBB3 Pathway Activation Induces Acquired Resistance to XPO1 Inhibitors

Takahito M. Miyake, Sunila Pradeep, Emine Bayraktar, Elaine Stur, Katelyn F. Handley, Sherry Y. Wu, Cristian Rodriguez-Aguayo, Ju-Seog Lee, Gabriel Lopez-Berestein, Robert L. Coleman, Anil K. Sood
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2020) 19 (8): 1727–1735.
https://doi.org/10.1158/1535-7163.MCT-19-0977
Published: 04 August 2020
View article titled, NRG1/ERBB3 Pathway Activation Induces Acquired Resistance to XPO1 Inhibitors
Open the PDF for NRG1/ERBB3 Pathway Activation Induces Acquired Resistance to XPO1 Inhibitors in another window
Includes: Supplementary data
Journal Articles

GnRH-R–Targeted Lytic Peptide Sensitizes BRCA Wild-type Ovarian Cancer to PARP Inhibition

Shaolin Ma, Sunila Pradeep, Alejandro Villar-Prados, Yunfei Wen, Emine Bayraktar, Lingegowda S. Mangala, Mark Seungwook Kim, Sherry Y. Wu, Wei Hu, Cristian Rodriguez-Aguayo, Carola Leuschner, Xiaoyan Liang, Prahlad T. Ram, Katharina Schlacher, Robert L. Coleman, Anil K. Sood
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2019) 18 (5): 969–979.
https://doi.org/10.1158/1535-7163.MCT-18-0770
Published: 01 May 2019
View article titled, GnRH-R–Targeted Lytic Peptide Sensitizes <em>BRCA</em> Wild-type Ovarian Cancer to PARP Inhibition
Open the PDF for GnRH-R–Targeted Lytic Peptide Sensitizes <em>BRCA</em> Wild-type Ovarian Cancer to PARP Inhibition in another window
Includes: Supplementary data
Journal Articles

Inhibiting Nuclear Phospho-Progesterone Receptor Enhances Antitumor Activity of Onapristone in Uterine Cancer

Yan Huang, Wei Hu, Jie Huang, Fangrong Shen, Yunjie Sun, Cristina Ivan, Sunila Pradeep, Robert Dood, Monika Haemmerle, Dahai Jiang, Lingegowda S. Mangala, Kyunghee Noh, Jean M. Hansen, Heather J. Dalton, Rebecca A. Previs, Archana S. Nagaraja, Michael McGuire, Nicholas B. Jennings, Russell Broaddus, Robert L. Coleman, Anil K. Sood
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2018) 17 (2): 464–473.
https://doi.org/10.1158/1535-7163.MCT-17-0006
Published: 01 February 2018
View article titled, Inhibiting Nuclear Phospho-Progesterone Receptor Enhances Antitumor Activity of Onapristone in Uterine Cancer
Open the PDF for Inhibiting Nuclear Phospho-Progesterone Receptor Enhances Antitumor Activity of Onapristone in Uterine Cancer in another window
Includes: Supplementary data
Journal Articles

Abstract LB-A12: Results from the phase 3 study ARIEL3: mutations in non-BRCA homologous recombination repair genes confer sensitivity to maintenance treatment with the PARP inhibitor rucaparib in patients with recurrent platinum-sensitive high-grade ovarian carcinoma

David M. O'Malley, Robert L. Coleman, Amit M. Oza, Domenica Lorusso, Carol Aghajanian, Ana Oaknin, Andrew Dean, Nicoletta Colombo, Iain A. McNeish, Elizabeth M. Swisher, Clare L. Scott, Gottfried E. Konecny, Heidi Giordano, Terri Cameron, Lara Maloney, Sandra Goble, James Sun, Thomas C. Harding, Kevin K. Lin, Jonathan A. Ledermann
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2018) 17 (1_Supplement): LB-A12.
https://doi.org/10.1158/1535-7163.TARG-17-LB-A12
Published: 01 January 2018
View article titled, Abstract LB-A12: Results from the phase 3 study ARIEL3: mutations in non-<em>BRCA</em> homologous recombination repair genes confer sensitivity to maintenance treatment with the PARP inhibitor rucaparib in patients with recurrent platinum-sensitive high-grade ovarian carcinoma
Journal Articles

Preclinical Mammalian Safety Studies of EPHARNA (DOPC Nanoliposomal EphA2-Targeted siRNA)

Michael J. Wagner, Rahul Mitra, Mark J. McArthur, Wallace Baze, Kirstin Barnhart, Sherry Y. Wu, Cristian Rodriguez-Aguayo, Xinna Zhang, Robert L. Coleman, Gabriel Lopez-Berestein, Anil K. Sood
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2017) 16 (6): 1114–1123.
https://doi.org/10.1158/1535-7163.MCT-16-0541
Published: 01 June 2017
View article titled, Preclinical Mammalian Safety Studies of EPHARNA (DOPC Nanoliposomal EphA2-Targeted siRNA)
Open the PDF for Preclinical Mammalian Safety Studies of EPHARNA (DOPC Nanoliposomal EphA2-Targeted siRNA) in another window
Includes: Supplementary data
Journal Articles

Dll4 Inhibition plus Aflibercept Markedly Reduces Ovarian Tumor Growth

Jie Huang, Wei Hu, Limin Hu, Rebecca A. Previs, Heather J. Dalton, Xiao-Yun Yang, Yunjie Sun, Michael McGuire, Rajesha Rupaimoole, Archana S. Nagaraja, Yu Kang, Tao Liu, Alpa M. Nick, Nicholas B. Jennings, Robert L. Coleman, Robert B. Jaffe, Anil K. Sood
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2016) 15 (6): 1344–1352.
https://doi.org/10.1158/1535-7163.MCT-15-0144
Published: 02 June 2016
View article titled, Dll4 Inhibition plus Aflibercept Markedly Reduces Ovarian Tumor Growth
Open the PDF for Dll4 Inhibition plus Aflibercept Markedly Reduces Ovarian Tumor Growth in another window
Includes: Supplementary data
Journal Articles

Dual Metronomic Chemotherapy with Nab-Paclitaxel and Topotecan Has Potent Antiangiogenic Activity in Ovarian Cancer

Rebecca A. Previs, Guillermo N. Armaiz-Pena, Yvonne G. Lin, Ashley N. Davis, Sunila Pradeep, Heather J. Dalton, Jean M. Hansen, William M. Merritt, Alpa M. Nick, Robert R. Langley, Robert L. Coleman, Anil K. Sood
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2015) 14 (12): 2677–2686.
https://doi.org/10.1158/1535-7163.MCT-14-0630
Published: 06 December 2015
View article titled, Dual Metronomic Chemotherapy with Nab-Paclitaxel and Topotecan Has Potent Antiangiogenic Activity in Ovarian Cancer
Open the PDF for Dual Metronomic Chemotherapy with Nab-Paclitaxel and Topotecan Has Potent Antiangiogenic Activity in Ovarian Cancer in another window
Includes: Supplementary data
Journal Articles

PTEN Expression as a Predictor of Response to Focal Adhesion Kinase Inhibition in Uterine Cancer

Duangmani Thanapprapasr, Rebecca A. Previs, Wei Hu, Cristina Ivan, Guillermo N. Armaiz-Pena, Piotr L. Dorniak, Jean M. Hansen, Rajesha Rupaimoole, Jie Huang, Heather J. Dalton, Rouba Ali-Fehmi, Robert L. Coleman, Anil K. Sood
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2015) 14 (6): 1466–1475.
https://doi.org/10.1158/1535-7163.MCT-14-1077
Published: 04 June 2015
View article titled, <em>PTEN</em> Expression as a Predictor of Response to Focal Adhesion Kinase Inhibition in Uterine Cancer
Open the PDF for <em>PTEN</em> Expression as a Predictor of Response to Focal Adhesion Kinase Inhibition in Uterine Cancer in another window
Includes: Supplementary data
Journal Articles

Targeting Aldehyde Dehydrogenase Cancer Stem Cells in Ovarian Cancer

Charles N. Landen, Jr, Blake Goodman, Ashwini A. Katre, Adam D. Steg, Alpa M. Nick, Rebecca L. Stone, Lance D. Miller, Pablo Vivas Mejia, Nicolas B. Jennings, David M. Gershenson, Robert C. Bast, Jr., Robert L. Coleman, Gabriel Lopez-Berestein, Anil K. Sood
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2010) 9 (12): 3186–3199.
https://doi.org/10.1158/1535-7163.MCT-10-0563
Published: 14 December 2010
View article titled, Targeting Aldehyde Dehydrogenase Cancer Stem Cells in Ovarian Cancer
Open the PDF for Targeting Aldehyde Dehydrogenase Cancer Stem Cells in Ovarian Cancer in another window
Includes: Supplementary data
Journal Articles

Converging Evidence for Efficacy from Parallel EphB4-Targeted Approaches in Ovarian Carcinoma

Whitney A. Spannuth, Lingegowda S. Mangala, Rebecca L. Stone, Amy R. Carroll, Masato Nishimura, Mian M.K. Shahzad, Sun-Joo Lee, Myrthala Moreno-Smith, Alpa M. Nick, Ren Liu, Nicholas B. Jennings, Yvonne G. Lin, William M. Merritt, Robert L. Coleman, Pablo E. Vivas-Mejia, Yue Zhou, Valery Krasnoperov, Gabriel Lopez-Berestein, Parkash S. Gill, Anil K. Sood
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2010) 9 (8): 2377–2388.
https://doi.org/10.1158/1535-7163.MCT-10-0200
Published: 09 August 2010
View article titled, Converging Evidence for Efficacy from Parallel EphB4-Targeted Approaches in Ovarian Carcinoma
Open the PDF for Converging Evidence for Efficacy from Parallel EphB4-Targeted Approaches in Ovarian Carcinoma in another window
Includes: Supplementary data
Journal Articles

Bridging the Gap between Cytotoxic and Biologic Therapy with Metronomic Topotecan and Pazopanib in Ovarian Cancer

William M. Merritt, Alpa M. Nick, Amy R. Carroll, Chunhua Lu, Koji Matsuo, Melissa Dumble, Nicholas Jennings, ShuYun Zhang, Yvonne G. Lin, Whitney A. Spannuth, Aparna A. Kamat, Rebecca L. Stone, Mian M.K. Shahzad, Robert L. Coleman, Rakesh Kumar, Anil K. Sood
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2010) 9 (4): 985–995.
https://doi.org/10.1158/1535-7163.MCT-09-0967
Published: 07 April 2010
View article titled, Bridging the Gap between Cytotoxic and Biologic Therapy with Metronomic Topotecan and Pazopanib in Ovarian Cancer
Open the PDF for Bridging the Gap between Cytotoxic and Biologic Therapy with Metronomic Topotecan and Pazopanib in Ovarian Cancer in another window
Includes: Supplementary data